Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
Company profile
Ticker
TRIL
Exchange
Website
CEO
Jan Skvarka
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Trillium Therapeutics USA Inc. ...
TRIL stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
29 Nov 21
EFFECT
Notice of effectiveness
22 Nov 21
EFFECT
Notice of effectiveness
22 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 21
POSASR
Automatic shelf registration (post-effective amendment)
17 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 21
POS AM
Prospectus update (post-effective amendment)
17 Nov 21
POS AM
Prospectus update (post-effective amendment)
17 Nov 21
8-K
Pfizer Completes Acquisition of Trillium Therapeutics
17 Nov 21
25-NSE
Exchange delisting
17 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 93.23 mm | 93.23 mm | 93.23 mm | 93.23 mm | 93.23 mm | 93.23 mm |
Cash burn (monthly) | 25.54 mm | 12.86 mm | 6.48 mm | 4.79 mm | 5.67 k | 1.41 mm |
Cash used (since last report) | 788.91 mm | 397.41 mm | 200.30 mm | 147.96 mm | 175.06 k | 43.59 mm |
Cash remaining | -695.69 mm | -304.19 mm | -107.07 mm | -54.73 mm | 93.05 mm | 49.63 mm |
Runway (months of cash) | -27.2 | -23.6 | -16.5 | -11.4 | 16420.9 | 35.2 |
Institutional ownership, Q1 2023
10.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 99.54 mm |
Total shares | 10.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities V | 6.59 mm | $40.11 mm |
Venrock Healthcare Capital Partners III | 4.04 mm | $59.43 mm |